Tue Dec 03 13:30:00 UTC 2024: ## Granules India Stock Plummets After US FDA Issues “Official Action Indicated”
**MUMBAI, INDIA** – Shares of Granules India fell nearly 10% on [Date] after the company disclosed that the US Food and Drug Administration (FDA) has issued an “Official Action Indicated” (OAI) classification following an inspection of its Gagillapur facility in Hyderabad.
The FDA’s inspection, conducted from August 26 to September 6, resulted in six observations detailed in a Form 483. While Granules India claims to have responded to all observations and is undertaking a comprehensive facility evaluation with external experts, the OAI classification signals potential ongoing compliance issues.
The Hyderabad facility is a major revenue contributor for Granules India, and the OAI could lead to extended delays in resolving the issues. A worst-case scenario could involve a warning letter, or even an import alert, significantly impacting the company’s operations and financial performance.
The company previously stated that the facility’s issues would have a “small spillover” into the third quarter of fiscal year 25, but the OAI suggests a potentially more prolonged impact. The company’s Q2FY25 standalone sales were already down 43.73% year-on-year at Rs 567.99 crore.
Granules India assures investors that it is working to regain compliance and is confident of securing approval from the US FDA. However, the market reacted negatively to the news, highlighting the significant regulatory challenges facing the pharmaceutical company. The situation underscores the importance of maintaining stringent quality control standards for companies exporting products to the US market.
First Piper 